Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Gets CDC Contract to Develop Flu Tests

NEW YORK (GenomeWeb News) – Nanogen said today that it has been awarded a two-year, $10.4 million contract from the US Centers for Disease Control and Prevention to develop multi-analyte molecular diagnostic tests for influenza.
 
Under the contract, San Diego-based Nanogen will develop a rapid molecular test that simultaneously detects and differentiates influenza type A and type B, seasonal flu (H1N1 and H3N2) strains, and respiratory syncytial virus. The firm also will develop a secondary test for avian flu strains including H5N1, H7N1, and H9N1, to be available for samples testing positive for flu A but negative for seasonal flu.
 
Nanogen said it would develop the tests in combination with the Medical College of Wisconsin and HandyLab, and it expects the tests to be more sensitive and quicker than currently available molecular diagnostic assays for flu. Nanogen said that the proposal presented to the CDC said that it would use its MGB probe technology in combination with HandyLab’s Raider instrument, a microfluidic real-time PCR-based system.
 
Nanogen also is developing a rapid, point-of-care flu test for the CDC, under a contract signed in December 2006.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.